European Archives of Oto-Rhino-Laryngology

, Volume 273, Issue 9, pp 2305–2317 | Cite as

The prognostic and predictive value of excision repair cross-complementation group 1 (ERCC1) protein in 1288 patients with head and neck squamous cell carcinoma treated with platinum-based therapy: a meta-analysis

  • Vesna BišofEmail author
  • Matea Zajc Petranović
  • Zoran Rakušić
  • Kristina Ruža Samardžić
  • Antonio Juretić
Review Article


Excision repair cross-complementation group 1 (ERCC1) protein has been extensively investigated as a prognostic and predictive factor for platinum-based treatment in head and neck squamous cell carcinoma (HNSCC) but with inconsistent results. We performed the present meta-analysis to better elucidate this issue in advanced HNSCC. A literature search was conducted using the PubMed and Web of Science databases. The inclusion criteria were head and neck cancer patients with platinum-based treatment and evaluation of the correlation between ERCC1 expression and clinical outcomes [objective response rate (ORR), progression-free survival (PFS), and overall survival (OS), both unadjusted and adjusted estimates]. In high vs. low pooled analyses, high ERCC1 expression was associated with unfavorable OS [hazard ratio (HR) = 1.95, 95 % confidence interval (CI) 1.18–3.21, p = 0.009], PFS (HR = 2.39, 95 % CI 1.74–3.28, p = 0.000) and ORR (odds ratio = 0.48, 95 % CI 0.23–0.98, p = 0.044). In the subgroup analysis of adjusted OS estimates, ERCC1 was a predictor of shorter survival in Asians (HR = 3.13, 95 % CI 2.09–4.70, p = 0.000) and Caucasians (HR = 2.02, 95 % CI 1.32–3.07, p = 0.001) but of longer survival in South Americans (HR = 0.17, 95 % CI 0.07–0.40, p = 0.000). Immunohistochemistry proved to be of predictive value irrespective of used antibody (p = 0.009). In the stratified analysis according to the tumor site, ERCC1 expression was associated with OS in nasopharyngeal cancer (HR = 2.72, 95 % CI 1.79–4.13, p = 0.000). ERCC1 has a potential to become predictive and prognostic factor enabling treatment tailoring in HNSCC patients.


ERCC1 Platinum-based chemotherapy HNSCC Chemoradiotherapy Meta-analysis 


Conflict of interest


Supplementary material

405_2015_3710_MOESM1_ESM.pdf (100 kb)
Supplementary material 1 (PDF 100 kb)


  1. 1.
    Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A (2015) Global cancer statistics, 2012. CA Cancer J Clin 65:87–108CrossRefPubMedGoogle Scholar
  2. 2.
    Gregoire V, Lefebvre J-L, Licitra L, Felip E (2010) Squamous cell carcinoma of the head and neck: EHNS-ESMO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 21(suppl. 5):vi184–vi186Google Scholar
  3. 3.
    Tang C, Chan C, Jiang W, Murphy JD, von Eyben R, Colevas AD, Pinto H, Lee-Enriquez N, Kong C, Le QT (2015) Concurrent cetuximab versus platinum-based chemoradiation for the definitive treatment of locoregionally advanced head and neck cancer. Head Neck 37:386–392CrossRefPubMedGoogle Scholar
  4. 4.
    Pignon JP, le Maître Maillard E, Bourhis J, MACH-NC Collaborative Group (2009) Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomized trials and 17,346 patients. Radiother Oncol 92:4–14CrossRefPubMedGoogle Scholar
  5. 5.
    Galluzzi L, Vitale I, Michels J, Brenner C, Szabadkai G, Harel-Bellan A, Castedo M, Kroemer G (2014) Systems biology of cisplatin resistance: past, present and future. Cell Death Dis. doi: 10.1038/cddis.2013.428 PubMedPubMedCentralGoogle Scholar
  6. 6.
    Damia G, Imperatori L, Stefanini M, D’Incalci M (1996) Sensitivity of CHO mutant cell lines with specific defects in nucleotide excision repair to different anticancer agents. Int J Cancer 66:779–783CrossRefPubMedGoogle Scholar
  7. 7.
    Bowden NA (2014) Nucleotide excision repair: why is it not to predict response to platinum-based chemotherapy? Cancer Lett 346:163–171CrossRefPubMedGoogle Scholar
  8. 8.
    Niedernhofer LJ, Odijk H, Budzowska M, van Drunen E, Maas A, Theil AF, de Wit J, Jaspers NGJ, Berna Beverloo H, Hoeijmakers JHJ, Kanaar R (2004) The structure-specific endonuclease ERCC1-Xpf is required to resolve DNA interstrand cross-link-induced double-strand breaks. Mol Cell Biol 24:5776–5787CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Bergstralh DT, Sekelsky J (2008) Interstrand crosslink repair: can XPF-ERCC1 be let off the hook? Trends Genet 24:70–76CrossRefPubMedGoogle Scholar
  10. 10.
    Ahmad A, Robinson AR, Duensing A, van Drunen E, Berna Beverloo H, Weisberg H, Hasty P, Hoeijmakers JHJ, Niedernhofer LJ (2008) ERCC1-XPF endonuclease facilitates DNA double-strand break repair. Mol Cell Biol 28:5082–5092CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    De Castro G, Pasini FS Jr, Siqueira SA, Ferraz AR, Villar RC, Snitcovsky IM, Federico MH (2011) ERCC1 protein, mRNA expression and T19007C polymorphism as prognostic markers in head and neck squamous cell carcinoma patients treated with surgery and adjuvant cisplatin-based chemoradiation. Oncol Rep 25:693–699Google Scholar
  12. 12.
    Jun HJ, Ahn MJ, Kim HS, Yi SY, Han J, Lee SK, Ahn YC, Jeong H-S, Son Y-I, Baek J-H, Park K (2008) ERCC1 expression as a predictive marker of squamous cell carcinoma of the head and neck treated with cisplatin-based concurrent chemoradiation. Br J Cancer 99:167–172CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Hayes M, Lan C, Yan J, Xie Y, Gray T, Amirkhan RH, Dowell JE (2012) ERCC1 expression and outcome in head and neck cancer treated with concurrent cisplatin and radiation. Anticancer Res 31:4135–4140Google Scholar
  14. 14.
    Bauman JE, Austin MC, Scmidt R, Kurland BF, Vaezi A, Hayes DN, Mendez E, Parvathaneni U, Chai X, Sampath S, Martins RG (2013) ERCC1 is a prognostic biomarker in locally advanced head and neck cancer: results from a randomized, phase II trial. Br J Cancer 109:2096–2105CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Hao D, Lau HY, Eliasziw M, Box A, Diaz R, Klimowicz AC, Shin B, Lees-Miller S, Magliocco AM (2012) Comparing ERCC1 protein expression, mRNA levels and genotype in squamous cell carcinomas of the head and neck treated with concurrent chemoradiation stratified by HPV status. Head Neck 34:785–791CrossRefPubMedGoogle Scholar
  16. 16.
    Xuelei M, Jingwen H, Wei D, Hongyu Z, Jing Z, Changle S, Lei L (2015) ERCC1 plays an important role in predicting survival outcomes and treatment response for patients with HNSCC: a meta-analysis. Oral Oncol 51:483–492CrossRefPubMedGoogle Scholar
  17. 17.
    Gao Y, Liu D (2015) The roles of excision repair cross-complementation group 1 in objective response after cisplatin-based concurrent chemoradiotherapy and survival in head and neck cancer: a systematic review and meta-analysis. Oral Oncol 51:570–577CrossRefPubMedGoogle Scholar
  18. 18.
    Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group (2009) Preferred reporting items for systemic reviews and meta-analyses: the PRISMA statement. PLoS Med. doi: 10.1371/journal.pmed.1000097
  19. 19.
    Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes M (2007) Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. doi: 10.1186/1745-6215-8-16 PubMedPubMedCentralGoogle Scholar
  20. 20.
    DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177–188CrossRefPubMedGoogle Scholar
  21. 21.
    Mantel N, Haenszel W (1959) Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22:719–748PubMedGoogle Scholar
  22. 22.
    Chiu T-J, Chen C-H, Chien C-Y, Li S-H, Tsai H-T, Chen Y-J (2011) High ERCC1 expression predicts cisplatin-based chemotherapy resistance and poor outcome in unresectable squamous cell carcinoma of head and neck in betel-chewing area. J Transl Med. doi: 10.1186/1479-5876-9-31 PubMedPubMedCentralGoogle Scholar
  23. 23.
    Fountzilas G, Kalogera-Fountzila A, Lambaki S, Wirtz RM, Nikolaou A, Karayannopoulou G, Bobos M, Kotoula V, Murray S, Lambropoulos A, Asravantinos G, Markou K, Athanassiou E, Misailidou D, Kalogeras KT, Skarlos D (2009) MMP9 but not EGFR, MET, ERCC1, P16 and P-53 is associated with response to concomitant radiotherapy, cetuximab and weekly cisplatin in patients with locally advanced head and neck cancer. J Oncol. doi: 10.1155/2009/305908 Google Scholar
  24. 24.
    Fountzilas G, Bamias A, Kalogera-Fountzila A, Karayannopoulou G, Bobos M, Athanassiou E, Kalogeras KT, Tolis C, Tsekeris P, Papakostas P, Vamvouka C, Zaramboukas T, Kosmidis P, Zamboglou N, Misailidou D (2009) Induction chemotherapy with docetaxel and cisplatin followed by concomitant chemoradiotherapy in patients with inoperable non-nasopharyngeal carcinoma of the head and neck. Anticancer Res 29:529–538PubMedGoogle Scholar
  25. 25.
    Handra-Luca A, Hernandez J, Mountzios G, Taranchon E, Lacau-St-Guily J, Soria J-C, Fouret P (2007) Excision repair cross complementation group 1 immunohistochemical expression predicts objective response and cancer-specific survival in patients treated by cisplatin-based induction chemotherapy for locally advanced head and neck squamous cell carcinoma. Clin Cancer Res 13:3855–3859CrossRefPubMedGoogle Scholar
  26. 26.
    Huang P-Y, Li Y, Mai H-Q, Luo R-Z, Cai Y-C, Li Zhang (2012) Expression of ERCC1 predicts clinical outcome in locoregionally advanced nasopharyngeal carcinoma treated with cisplatin—based induction chemotherapy. Oral Oncol 48:964–968CrossRefPubMedGoogle Scholar
  27. 27.
    Jagdis A, Phan T, Klimowicz AC, Laskin JJ, Lau H, Petrillo SK, Siever JE, Thomson TA, Magliocco AM, Hao D (2013) Assessment of ERCC1 and XPF protein expression using quantitative immunohistochemistry in nasopharyngeal carcinoma patients undergoing curative intent treatment. Int J Radiation Oncol Biol Phys 85:1340–1345CrossRefGoogle Scholar
  28. 28.
    Krikelis D, Bobos M, Karayannopoulou G, Resiga L, Chrysafi S, Samantas E, Andreopoulos D, Vassiliou V, Cluleanu E, Fountzilas G (2013) Expression profiling of 21 biomolecules in locally advanced nasopharyngeal carcinomas of Caucasian patients. BMC Clin Pathol. doi: 10.1186/1472-6890-13-1 PubMedPubMedCentralGoogle Scholar
  29. 29.
    Lee HW, Hwang YH, Han HJH, Choi J-H, Kang SY, Jeong SH, Ann MS, Oh YT, Kim JH, Kim CH, Sheen SS (2010) High expression of excision repair cross-complementation group 1 protein predicts poor outcome in patients with nasopharyngeal cancer. Oral Oncol 46:209–213CrossRefPubMedGoogle Scholar
  30. 30.
    Park Y, Kim DS, Park KH, Baek S-K, Kwon SY, Shin SW, Jung KY, Kim CY, Kim YH, Lee NJ, Kim JS, Kim IS (2012) RASSF1A and ERCC1 expression levels might be predictive of prognosis in advanced, recurrent and metastatic squamous cell carcinoma of the head and neck treated with docetaxel and cisplatin. Onkologie 35:673–682CrossRefPubMedGoogle Scholar
  31. 31.
    Patel MR, Zhao N, Ang M-K, Stadler ME, Fritchie K, Weisslier MC, Zanation AM, Harris SL, Funkhouser WK, Olshan AF, Shores CG, Hayes DN (2013) ERCC1 protein expression is associated with differential survival in oropharyngeal head and neck squamous cell carcinoma. Otolaryngol Head Neck Surg 149:587–595CrossRefPubMedGoogle Scholar
  32. 32.
    Sun J-M, Ahn M-J, Park MJ, Lee H-Y, Ahn JS, Lee S, Kang G, Han J, Son Y-I, Baek C-H, Ahn YC, Park K (2011) Expression of excision repair cross-complementation group 1 as predictive marker for nasopharyngeal cancer treated with concurrent chemoradiotherapy. Int J Radiation Oncol Biol Phys 80:655–660CrossRefGoogle Scholar
  33. 33.
    Zhang Z, Jiang C, Hu L (2014) Low expression of excision repair cross-complementation group-1 protein predicts better outcome in patients with locally advanced nasopharyngeal cancer treated with concurrent chemoradiotherapy. Tumori 100:328–332PubMedGoogle Scholar
  34. 34.
    McNeil EM, Melton DW (2012) DNA repair endonuclease ERCC1-XPF as a novel therapeutic target to overcome chemoresistance in cancer therapy. Nucleic Acids Res 40:9990–10004CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Nix P, Greenman J, Cawkwell L (2004) Expression of XRCC1 and ERCC1 proteins in radioresistant and radiosensitive laryngeal cancer. Cancer Therapy 2:47–53Google Scholar
  36. 36.
    Johung KL, Rewari A, Wu H, Contessa J, Haffty B, Decker RH (2013) Role of excision repair cross-complementation 1 expression as a prognostic marker for response to radiotherapy in early stage laryngeal cancer. Head Neck 35:852–857CrossRefPubMedGoogle Scholar
  37. 37.
    Bišof V, Jakovčević A, Seiwerth S, Rakušić Z, Gašparov S (2013) Prognostic value of ERCC1 in head and neck carcinoma treated with definitive or adjuvant radiotherapy. J Cancer Res Clin Oncol 139:187–194CrossRefPubMedGoogle Scholar
  38. 38.
    Dudas J, Schartinger VH, Romani A, Schweigl G, Kordsmeyer K, Marta PI, Url C, Kral F, Riechelmann H (2014) Cell cycle association and hypoxia regulation of excision repair cross complementation group 1 protein (ERCC1) in tumor cells of head and neck cancer. Tumor Biol 35:7807–7819CrossRefGoogle Scholar
  39. 39.
    Taillade L, Penault-Llorca F, Boulet T, Fouret P, Michiels S, Taranchon E, Mountzios G, Validire P, Domont J, Girard P, Grunenwald D, Le Chevalier T, Soria JC (2007) Immunohistochemichal expression of biomarkers: a comparative study between diagnostic bronchial biopsies and surgical specimens of non-small cell lung cancer. Ann Oncol 18:1043–1050CrossRefPubMedGoogle Scholar
  40. 40.
    Babic A, Loftin IR, Stanislaw S, Wang M, Miller R, Warren SM, Zhang W, Lau A, Miller M, Wu P, Padilla M, Grogan TM, Pesrtic-Dragovich L, McElhinny AS (2010) The impact of pre-analytical processing on staining quality for H&E, dual hapten, dual color in situ hybridization assays. Methods 52:287–300CrossRefPubMedGoogle Scholar
  41. 41.
    Taylor CR, Levenson RM (2006) Quantification of immunohistochemistry-issues concerning methods, utility and semiquantitative assessment II. Histopathology 49:411–424CrossRefPubMedGoogle Scholar
  42. 42.
    Niedernhofer LJ, Bhagwat N, Wood RD (2007) ERCC1 and non-small cell lung cancer. N Engl J Med 356:2538–2540CrossRefPubMedGoogle Scholar
  43. 43.
    Bhagwat NR, Roginskaya VY, Acquafondata MB, Dhir R, Wood RD, Niedernhofer LJ (2009) Immunodetection of DNA repair endonuclease ERCC1-XPF in human tissue. Cancer Res 69:6831–6838CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    Ma D, Baruch D, Shu Y, Yuan K, Sun Z, Ma K, Hoang T, Fu W, Min L, Lan ZS, Wang F, Mull L, He WW (2012) Using protein microarray technology to screen anti-ERCC1 monoclonal antibodies for specificity and applications in pathology. BMC Biotechnol. doi: 10.1186/1472-6750-12-88 Google Scholar
  45. 45.
    Vaezi AE, Bepler G, Bhagwat NR, Malysa A, Rubatt JM, Chen W, Hood BL, Conrads TP, Wang L, Kemp CE, Niedernhofer LJ (2014) Choline phosphate cytidylyltransferase-α is a novel antigen detected by the anti-ERCC1 antibody 8F1 with biomarker value in patients with lung and head and neck squamous cell carcinomas. Cancer 120:1898–1907CrossRefPubMedPubMedCentralGoogle Scholar
  46. 46.
    Friboulet L, Olasussen KA, Pignon J-P, Shepherd FA, Tsao M-S, Graziano S, Kratzke R, Douillard J-Y, Seymour L, Pirker R, Filipits M, André F, Solary E, Ponsonnailles F, Robin A, Stoclin A, Dorvault N, Commo F, Adam J, Vanhecke E, Saulnier P, Thomale J, Le Chevalier T, Dunant A, Rousseau V, Le Teuff G, Brambilla E, Soria J-C (2013) ERCC1 isoform expression and DNA repair in non-small-cell lung cancer. N Engl J Med 368:1101–1110CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2015

Authors and Affiliations

  • Vesna Bišof
    • 1
    • 2
    Email author
  • Matea Zajc Petranović
    • 3
  • Zoran Rakušić
    • 1
  • Kristina Ruža Samardžić
    • 1
  • Antonio Juretić
    • 1
    • 4
  1. 1.Department of OncologyUniversity Hospital Centre ZagrebZagrebCroatia
  2. 2.School of MedicineUniversity of OsijekOsijekCroatia
  3. 3.Institute for Anthropological ResearchZagrebCroatia
  4. 4.School of MedicineUniversity of ZagrebZagrebCroatia

Personalised recommendations